Shanghai Medicilon Inc. (SHA:688202)

Market Cap	7.77B
Revenue (ttm)	1.04B
Net Income (ttm)	-330.85M
Shares Out	133.35M
EPS (ttm)	-2.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,210,977
Average Volume	10,301,265
Open	61.59
Previous Close	61.60
Day's Range	59.80 - 63.05
52-Week Range	23.30 - 71.71
Beta	0.87
RSI	54.89
Earnings Date	Aug 29, 2025

About Shanghai Medicilon

Shanghai Medicilon Inc., a contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. The company operates through Drug Discovery and Pharmaceutical Research, and Preclinical Research segments. It offers medicinal and analytical chemistry; process development services; custom and zoom in synthesis; structural, in vitro, and computational biology; protein expression and purification; protein crystallization; and recombinant kinase preparation servic...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2004
• Employees: 2,349
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688202

Financial Performance

In 2024, Shanghai Medicilon's revenue was 1.04 billion, a decrease of -24.01% compared to the previous year's 1.37 billion. Losses were -330.85 million, 896.2% more than in 2023.